FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

MedWatch to Manufacturers Program Discontinued

[ Price : $8.95]

FDA drops the MedWatch to Manufacturers Program in favor of the FDA Adverse Events Reporting System public dashboard.

End Monopoly Control of Remdesivir: Public Citizen

[ Price : $8.95]

Public Citizen says Gileads remdesivir should be in the public domain because taxes help fund its development and the federal gove...

Biotricity Gains Clearance for Bioflux Software

[ Price : $8.95]

FDA clears a Biotricity 510(k) for its Bioflux Software II System.

FDA Nimble in Pandemic Responses: Azar

[ Price : $8.95]

HHS secretary Alex Azar says FDA moved quickly to remove KN95 masks from Chinese manufacturers that didnt have required independen...

Comments Sought on International Controls on 11 drugs

[ Price : $8.95]

Federal Register notice: FDA seeks comments on abuse potential, actual abuse, medical usefulness, trafficking, and impact of sched...

FDA Encouraging Advanced Manufacturing

[ Price : $8.95]

FDA commissioner Stephen Hahn and deputy commissioner for medical and scientific affairs Anand Shah describe agency steps to promo...

GSK, Sanofi Report Zantac-related Probes

[ Price : $8.95]

GlaxoSmithKline (XXX DELETE XXX)and Sanofi separately disclose that they are being investigated by the U.S. Justice Department ove...

Ex-FDA Commissioners Urge Coordinated Covid-19 Plasma Effort

[ Price : $8.95]

Four former FDA commissioners urge U.S. regulators, researchers and Covid-19-recovered patients to join in an effort to collect bl...

Biosimilar User Fee Rates for FY 2021

[ Price : $8.95]

Federal Register notice: FDA announces the rates for biosimilar user fees for fiscal year 2021.

Latest FDA Warning Letters

[ Price : $8.95]

FDA releases its latest batch of Warning Letters that includes Acrx Specialty Pharmacy, Fishman Chemical and MMSTabs.com.